Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCCG EPN23 multimodality therapy in pediatric intracranial ependymoma
jRCTs041240110Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial in ependymoma (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Stratum 1: Non unresectable recurrence rate, Stratum 2: Event-free survival in 2 years and 1 more. Started Dec 2024; status: recruiting.
02
Conditions
ependymoma
Beyond the preview
Go deeper on jRCTs041240110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240110.